Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Apyx Medical (APYX) Net Income towards Common Stockholders (2016 - 2025)

Apyx Medical (APYX) has disclosed Net Income towards Common Stockholders for 15 consecutive years, with -$1.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income towards Common Stockholders rose 71.93% year-over-year to -$1.3 million, compared with a TTM value of -$11.2 million through Dec 2025, up 52.22%, and an annual FY2025 reading of -$11.2 million, up 52.22% over the prior year.
  • Net Income towards Common Stockholders was -$1.3 million for Q4 2025 at Apyx Medical, up from -$2.0 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$1.0 million in Q2 2023 and bottomed at -$9.6 million in Q4 2023.
  • Average Net Income towards Common Stockholders over 5 years is -$4.6 million, with a median of -$4.7 million recorded in 2023.
  • The sharpest move saw Net Income towards Common Stockholders surged 81.3% in 2023, then tumbled 543.38% in 2024.
  • Year by year, Net Income towards Common Stockholders stood at -$2.0 million in 2021, then crashed by 201.74% to -$6.1 million in 2022, then tumbled by 58.4% to -$9.6 million in 2023, then skyrocketed by 51.83% to -$4.6 million in 2024, then soared by 71.93% to -$1.3 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for APYX at -$1.3 million in Q4 2025, -$2.0 million in Q3 2025, and -$3.8 million in Q2 2025.